Medicines planning
49 results
Applied filters
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for denosumab 60mg biosimilars
16 January 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
The licence and supporting evidence for aflibercept biosimilars
4 February 2026Aflibercept 2mg biosimilars are available for NHS use. Learn about supporting evidence and differences.
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.